Incyte (INCY) Stock Insights

INCY$114.62-1.25 -1.07%
BiotechnologyLarge CapHigh Quality
Compare
Market cap$23.36BEnterprise value$20.13BRevenue (TTM)$6.01BMarket positionTop 25%

Score

51
Neutral
Value
38
Quality
73
Growth
42

Insights

  • Revenue by product
  • Revenue by region
Revenue by product
PeriodValue
FY2012J A K A F I: 3700000.0
FY2013J A K A F I: 28300000.0
FY2014J A K A F I: 49000000.0
FY2016I C L U S I G: 29600000.0, J A K A F I: 852800000.0
FY2017I C L U S I G: 66900000.0, J A K A F I: 1100000000.0
FY2018I C L U S I G: 79936000.0, J A K A F I: 1581658000.0, Milestone And Contract Revenue: 180000000.0, Olumiant Royalty: 40086000.0
FY2019I C L U S I G: 89954000.0, J A K A F I: 1910881000.0, Milestone And Contract Revenue: 77500000.0, Olumiant Royalty: 80424000.0
FY2020I C L U S I G: 105002000.0, J A K A F I: 2215752000.0, Milestone And Contract Revenue: 205000000.0, Olumiant Royalty: 110920000.0, PEMAZYRE Royalty Revenues: 25884000.0, Tabrecta Royalty Revenues: 4144000.0
FY2021I C L U S I G: 4668000.0, J A K A F I: 337991000.0, M I N J U V I: 68531000.0, Milestone And Contract Revenue: 95000000.0, Olumiant Royalty: 220875000.0, OPZELURA: 4910000.0, PEMAZYRE Royalty Revenues: 109395000.0, Tabrecta Royalty Revenues: 10389000.0
FY2022I C L U S I G: 105838000.0, J A K A F I: 2740800000.0, M I N J U V I: 19654000.0, Milestone And Contract Revenue: 165000000.0, Olumiant Royalty: 134547000.0, OPZELURA: 128735000.0, PEMAZYRE Royalty Revenues: 84650000.0, Tabrecta Royalty Revenues: 15411000.0
FY2024I C L U S I G: 114319000.0, J A K A F I: 3210947000.0, M I N J U V I: 119236000.0, Milestone And Contract Revenue: 43000000.0, Olumiant Royalty: 135572000.0, OPZELURA: 508293000.0, PEMAZYRE Royalty Revenues: 83919000.0, Tabrecta Royalty Revenues: 22746000.0, ZYNYZ: 3185000.0
FY2025I C L U S I G: 134071000.0, J A K A F I: 3550244000.0, M I N J U V I: 144578000.0, Milestone And Contract Revenue: 150000000.0, Olumiant Royalty: 144600000.0, OPZELURA: 678455000.0, PEMAZYRE Royalty Revenues: 86727000.0, Tabrecta Royalty Revenues: 26702000.0, ZYNYZ: 66351000.0
Revenue by region
PeriodValue
FY2016Europe: 29600000.0
FY2017Europe: 66900000.0
FY2018Europe: 79900000.0
FY2019Europe: 90000000.0
FY2020Europe: 105000000.0, U [S]: 2600000000.0
FY2021Europe: 124100000.0, U [S]: 2900000000.0
FY2022Europe: 147000000.0, UNITED STATES: 3200000000.0
FY2024Europe: 260400000.0, U [S]: 4000000000.0
FY2025Europe: 323734000.0, U [S]: 4799941000.0

Incyte (INCY) Stock Insights

INCY price $114.62 -1.25 -1.07%

Ticker
INCY
Price
$114.62
Change
-1.25 -1.07%
Market cap
$23.36B
P/E
58.55
Forward P/E
14.85
Dividend yield
0.00%
Beta
0.78
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
51
Value
38
Quality
73
Growth
42

Stocklytics score rationale: value 38, quality 73, growth 42.

AI Score 65. Incyte Corporation has a market cap of $24.47 billion and a high price-to-earnings ratio of 57.16, indicating potential overvaluation. Despite strong gross profit margins of 92.69% and a solid current ratio of 3.84, the company has reported negative net income in recent quarters, which raises concerns about its profitability and growth sustainability

Insights

Revenue by product
PeriodValue
FY2012J A K A F I: 3700000.0
FY2013J A K A F I: 28300000.0
FY2014J A K A F I: 49000000.0
FY2016I C L U S I G: 29600000.0, J A K A F I: 852800000.0
FY2017I C L U S I G: 66900000.0, J A K A F I: 1100000000.0
FY2018I C L U S I G: 79936000.0, J A K A F I: 1581658000.0, Milestone And Contract Revenue: 180000000.0, Olumiant Royalty: 40086000.0
FY2019I C L U S I G: 89954000.0, J A K A F I: 1910881000.0, Milestone And Contract Revenue: 77500000.0, Olumiant Royalty: 80424000.0
FY2020I C L U S I G: 105002000.0, J A K A F I: 2215752000.0, Milestone And Contract Revenue: 205000000.0, Olumiant Royalty: 110920000.0, PEMAZYRE Royalty Revenues: 25884000.0, Tabrecta Royalty Revenues: 4144000.0
FY2021I C L U S I G: 4668000.0, J A K A F I: 337991000.0, M I N J U V I: 68531000.0, Milestone And Contract Revenue: 95000000.0, Olumiant Royalty: 220875000.0, OPZELURA: 4910000.0, PEMAZYRE Royalty Revenues: 109395000.0, Tabrecta Royalty Revenues: 10389000.0
FY2022I C L U S I G: 105838000.0, J A K A F I: 2740800000.0, M I N J U V I: 19654000.0, Milestone And Contract Revenue: 165000000.0, Olumiant Royalty: 134547000.0, OPZELURA: 128735000.0, PEMAZYRE Royalty Revenues: 84650000.0, Tabrecta Royalty Revenues: 15411000.0
FY2024I C L U S I G: 114319000.0, J A K A F I: 3210947000.0, M I N J U V I: 119236000.0, Milestone And Contract Revenue: 43000000.0, Olumiant Royalty: 135572000.0, OPZELURA: 508293000.0, PEMAZYRE Royalty Revenues: 83919000.0, Tabrecta Royalty Revenues: 22746000.0, ZYNYZ: 3185000.0
FY2025I C L U S I G: 134071000.0, J A K A F I: 3550244000.0, M I N J U V I: 144578000.0, Milestone And Contract Revenue: 150000000.0, Olumiant Royalty: 144600000.0, OPZELURA: 678455000.0, PEMAZYRE Royalty Revenues: 86727000.0, Tabrecta Royalty Revenues: 26702000.0, ZYNYZ: 66351000.0
Revenue by region
PeriodValue
FY2016Europe: 29600000.0
FY2017Europe: 66900000.0
FY2018Europe: 79900000.0
FY2019Europe: 90000000.0
FY2020Europe: 105000000.0, U [S]: 2600000000.0
FY2021Europe: 124100000.0, U [S]: 2900000000.0
FY2022Europe: 147000000.0, UNITED STATES: 3200000000.0
FY2024Europe: 260400000.0, U [S]: 4000000000.0
FY2025Europe: 323734000.0, U [S]: 4799941000.0

Insights · Forecast · Financials · Learn

Stocklytics home · Screener